Enzymatica
1.94 SEK -2.02%Be the first to follow this company
Enzymatica is a life science company that develops and sells medical devices for infection-related diseases. The products are based on barrier technology, which includes marine enzymes. The company's first product is ColdZyme® Mouth Spray which can prevent colds as well as shorten the illness period. The product has been launched on several markets and the strategy is to expand to more markets via partners. The company is headquartered in Lund.
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
First North Stockholm
ENZY
Daily low / high price
1.88 / 1.97
SEK
Market cap
336.36M SEK
Turnover
191.99K SEK
Volume
101K
Financial calendar
Extraordinary general meeting
06.08.2024
Interim report
07.11.2024
Annual report
18.02.2025
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Mats Andersson, privat och genom bolag | 22.4 % | 22.4 % |
Roosgruppen AB | 13.6 % | 13.6 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
Enzymatica AB: Enzymatica's Board of Directors updates the financial targets
Notice of Extraordinary General Meeting in Enzymatica AB (publ)
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools